Article Information
History
- March 26, 2021.
Article Versions
- You are currently viewing Version 1 of this article (March 26, 2021 - 12:00).
- Version 2 (March 28, 2021 - 09:48).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Xintong Li1,*,
- Anna Ostropolets2,*,
- Rupa Makadia3,
- Azza Shaoibi3,
- Gowtham Rao3,
- Anthony G. Sena3,6,
- Eugenia Martinez-Hernandez4,
- Antonella Delmestri1,
- Katia Verhamme6,
- Peter Rijnbeek6,
- Talita Duarte-Salles5,
- Marc Suchard7,8,
- Patrick Ryan2,3,
- George Hripcsak2 and
- Daniel Prieto-Alhambra1,6,#
- 1Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom
- 2Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA
- 3Janssen Research and Development, Titusville, NJ, USA
- 4Neurology Department, Hospital Clinic de Barcelona and University of Barcelona, Barcelona, Spain
- 5Fundacio Institut Universitari per a la recerca a l’Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
- 6Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
- 7Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA USA
- 8Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, UCLA, Los Angeles, CA, USA
- ↵#Corresponding author: Prof Daniel Prieto-Alhambra, Botnar Research Centre, Windmill Road, OX37LD, Oxford, United Kingdom, daniel.prietoalhambra{at}ndorms.ox.ac.uk
Posted March 26, 2021.
Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study
